108 related articles for article (PubMed ID: 32195178)
1. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon
Ma C; Zhang J; Tang D; Ye X; Li J; Mu N; Li Z; Liu R; Xiang L; Huang C; Jiang R
Front Oncol; 2020; 10():224. PubMed ID: 32195178
[No Abstract] [Full Text] [Related]
2. Multidisciplinary management of patients with non-small cell lung cancer with leptomeningeal metastasis in the tyrosine kinase inhibitor era.
Chen KY; Wu SG; Lai DM; Kuo LT; Huang AP
J Neurosurg; 2023 Jun; 138(6):1552-1560. PubMed ID: 36208438
[TBL] [Abstract][Full Text] [Related]
3. Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer.
Tang X; Hu X; Yuan L; Yang H; Luo Y; Liu D; Hu Q; Shan C; Lin T; Cai L; Zhou Z; Jin X; Lei M; Hong W
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38795257
[TBL] [Abstract][Full Text] [Related]
4. Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets.
Gong J; Hu S; Shan Q; Qin J; Han N; Xie F; Lu H
Ther Adv Med Oncol; 2024; 16():17588359241239293. PubMed ID: 38510678
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastasis from EGFR-Mutated Non-Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape.
Tang M; Xu M; Wang J; Liu Y; Liang K; Jin Y; Duan W; Xia S; Li G; Chu H; Liu W; Wang Q
Adv Sci (Weinh); 2024 May; ():e2306348. PubMed ID: 38696655
[TBL] [Abstract][Full Text] [Related]
6. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
Le X; Nadler E; Costa DB; Heymach JV
Target Oncol; 2024 Jan; 19(1):125. PubMed ID: 38070005
[No Abstract] [Full Text] [Related]
7. Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report.
Ma C; Wang S; Mu N; Li J; Liu M; Li L; Jiang R
Front Oncol; 2020; 10():1635. PubMed ID: 33014823
[No Abstract] [Full Text] [Related]
8. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.
Alexander M; Lin E; Cheng H
Curr Treat Options Oncol; 2020 Jul; 21(9):72. PubMed ID: 32725549
[TBL] [Abstract][Full Text] [Related]
11. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer.
Nevel KS; DiStefano N; Lin X; Skakodub A; Ogilvie SQ; Reiner AS; Pentsova E; Boire A
Neuro Oncol; 2020 May; 22(5):675-683. PubMed ID: 32352148
[TBL] [Abstract][Full Text] [Related]
12. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
[TBL] [Abstract][Full Text] [Related]
13. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
[TBL] [Abstract][Full Text] [Related]
14. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.
Zhen J; Wen L; Lai M; Zhou Z; Shan C; Li S; Lin T; Wu J; Wang W; Xu S; Liu D; Lu M; Zhu D; Chen L; Cai L; Zhou C
Radiat Oncol; 2020 Jul; 15(1):185. PubMed ID: 32736566
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Okuno T; Arakawa S; Yoshida T; Ohe Y
Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
[No Abstract] [Full Text] [Related]
16. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Jung HA; Woo SY; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Transl Lung Cancer Res; 2020 Oct; 9(5):1749-1758. PubMed ID: 33209598
[TBL] [Abstract][Full Text] [Related]
17. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Shijubou N; Sumi T; Kamada K; Sawai T; Yamada Y; Nakata H; Mori Y; Chiba H
Thorac Cancer; 2021 Mar; 12(6):989-992. PubMed ID: 33533191
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling.
Shen FF; Guo W; Tian RF; Guo Y; Yang YL; Song X
Transl Lung Cancer Res; 2020 Apr; 9(2):373-378. PubMed ID: 32420078
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: an emerging modality to checkmate brain metastasis.
Ahmad A; Khan P; Rehman AU; Batra SK; Nasser MW
Mol Cancer; 2023 Jul; 22(1):111. PubMed ID: 37454123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
